The Role of Plasmapheresis in Critical Illness

Critical Care Clinics

Volumn 28, Issue 3, 2012, Pages 453-468

  Nguyen, Trung C ^a,b   Kiss, Joseph E ^c   Goldman, Jordana R ^a   Carcillo, Joseph A ^c  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Liver failure; Rapidly progressive glomerulonephritis; Solid organ transplantation; Therapeutic plasma exchange; Thrombotic microangiopathy; Vasculitides

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CLOPIDOGREL; PHOSPHOLIPID ANTIBODY; TICLOPIDINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ABO INCOMPATIBLE SOLID ORGAN TRANSPLANTATION; ACUTE DISSEMINATED ENCEPHALOMYELITIS; ANCA ASSOCIATED VASCULITIS; ANTIPHOSPHOLIPID SYNDROME; AREFLEXIA; AUTONOMIC DYSFUNCTION; CENTRIFUGATION; CHOREA MINOR; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL FEATURE; CONTINUOUS HEMODIALYSIS; CRITICAL ILLNESS; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; EATON LAMBERT SYNDROME; ENZYME ACTIVITY; FULMINANT HEPATIC FAILURE; GRAFT VERSUS HOST REACTION; GUILLAIN BARRE SYNDROME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; HYPOREFLEXIA; LIVER TRANSPLANTATION; MORTALITY; MULTIPLE ORGAN FAILURE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; ORGAN TRANSPLANTATION; PAIN; PARALYSIS; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REVIEW; SEIZURE; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; WILSON DISEASE;

CRITICAL CARE; CRITICAL ILLNESS; EVIDENCE-BASED MEDICINE; HUMANS; PLASMA EXCHANGE; PLASMAPHERESIS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84862518893     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2012.04.009     Document Type: Review

References (100)

1. Szczepiorkowski Z.M., Winters J.L., Bandarenko N., et al. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010, 25(3):83-177.
2. Moake J.L. Thrombotic microangiopathies. N Engl J Med 2002, 347(8):589-600.
3. Asada Y., Sumiyoshi A., Hayashi T., et al. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 1985, 38(5):469-479.
4. Burke A.P., Mont E., Kolodgie F., et al. Thrombotic thrombocytopenic purpura causing rapid unexpected death: value of CD61 immunohistochemical staining in diagnosis. Cardiovasc Pathol 2005, 14(3):150-155.
5. Hosler G.A., Cusumano A.M., Hutchins G.M. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 2003, 127(7):834-839.
6. Tsai H.M., Chandler W.L., Sarode R., et al. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res 2001, 49(5):653-659.
7. Levy G.G., Nichols W.C., Lian E.C., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001, 413(6855):488-494.
8. Furlan M., Robles R., Galbusera M., et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998, 339(22):1578-1584.
9. Tsai H.M., Lian E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998, 339(22):1585-1594.
10. Bernardo A., Ball C., Nolasco L., et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004, 104(1):100-106.
11. Crawley J.T., Lam J.K., Rance J.B., et al. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005, 105(3):1085-1093.
12. Studt J.D., Hovinga J.A., Antoine G., et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005, 105(2):542-544.
13. Nolasco L.H., Turner N.A., Bernardo A., et al. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 2005, 106(13):4199-4209.
14. Ono T., Mimuro J., Madoiwa S., et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006, 107(2):528-534.
15. Rock G.A., Shumak K.H., Buskard N.A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991, 325(6):393-397.
16. Delvaeye M., Noris M., De Vriese A., et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361(4):345-357.
17. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361(17):1676-1687.
18. Kwon T., Dragon-Durey M.A., Macher M.A., et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2008, 23(6):2088-2090.
19. Levi M., Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999, 341(8):586-592.
20. Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol 2004, 124(5):567-576.
21. Churchwell K.B., McManus M.L., Kent P., et al. Intensive blood and plasma exchange for treatment of coagulopathy in meningococcemia. J Clin Apher 1995, 10(4):171-177.
22. Niewold T.B., Bundrick J.B. Disseminated intravascular coagulation due to cytomegalovirus infection in an immunocompetent adult treated with plasma exchange. Am J Hematol 2006, 81(6):454-457.
23. Stegmayr B.G., Banga R., Berggren L., et al. Plasma exchange as rescue therapy in multiple organ failure including acute renal failure. Crit Care Med 2003, 31(6):1730-1736.
24. van Deuren M., Frieling J.T., van der Ven-Jongekrijg J., et al. Plasma patterns of tumor necrosis factor-alpha (TNF) and TNF soluble receptors during acute meningococcal infections and the effect of plasma exchange. Clin Infect Dis 1998, 26(4):918-923.
25. Nguyen T.C., Han Y.Y., Kiss J.E., et al. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure*. Crit Care Med 2008, 36(10):2878-2887.
26. Nadel S., Goldstein B., Williams M.D., et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. The Lancet 2007, 369(9564):836-843.
27. Asherson R.A., Cervera R., de Groot P.G., et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003, 12(7):530-534.
28. Cervera R., Font J., Gomez-Puerta J.A., et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 2005, 64(8):1205-1209.
29. Flamholz R., Tran T., Grad G.I., et al. Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: beta(2)-glycoprotein I antibodies as a marker of response to therapy. J Clin Apher 1999, 14(4):171-176.
30. Cervera R., Bucciarelli S., Plasin M.A., et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun 2009, 32(3-4):240-245.
31. Uthman I., Shamseddine A., Taher A. The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome. Transfus Apher Sci 2005, 33(1):11-17.
32. Ruutu T., Barosi G., Benjamin R.J., et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007, 92(1):95-100.
33. Uderzo C., Bonanomi S., Busca A., et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 2006, 82(5):638-644.
34. George J.N., Li X., McMinn J.R., et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 2004, 44(2):294-304.
35. Elliott M.A., Nichols W.L., Plumhoff E.A., et al. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc 2003, 78(4):421-430.
36. Siami K., Kojouri K., Swisher K.K., et al. Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study. Transplantation 2008, 85(1):22-28.
37. Kennedy G.A., Kearey N., Bleakley S., et al. Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange. Bone Marrow Transplant 2010, 45(4):699-704.
38. Oran B., Donato M., Aleman A., et al. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant 2007, 13(4):469-477.
39. Christidou F., Athanasiadou A., Kalogiannidis P., et al. Therapeutic plasma exchange in patients with grade 2-3 hematopoietic stem cell transplantation-associated thrombotic thrombocytopenic purpura: a ten-year experience. Ther Apher Dial 2003, 7(2):259-262.
40. Zakarija A., Kwaan H.C., Moake J.L., et al. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl 2009, (112):S20-S24.
41. Bennett C.L., Kim B., Zakarija A., et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol 2007, 50(12):1138-1143.
42. Naseer N., Aijaz A., Saleem M.A., et al. Ticlopidine-associated thrombotic thrombocytopenic purpura. Heart Dis 2001, 3(4):221-223.
43. Pham P.T., Peng A., Wilkinson A.H., et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis 2000, 36(4):844-850.
44. Au W.Y., Lie A.K., Lam C.C., et al. Tacrolimus (FK 506) induced thrombotic thrombocytopenic purpura after ABO mismatched second liver transplantation: salvage with plasmapheresis and prostacyclin. Haematologica 2000, 85(6):659-662.
45. Gupta S., Ttan N., Topolsky D., et al. Thrombotic thrombocytopenic purpura induced by cyclosporin a after allogeneic bone marrow transplantation treated by red blood cell exchange transfusion: a case report. Am J Hematol 2005, 80(3):246-247.
46. Nakazawa Y., Hashikura Y., Urata K., et al. Von Willebrand factor-cleaving protease activity in thrombotic microangiopathy after living donor liver transplantation: a case report. Liver Transpl 2003, 9(12):1328-1333.
47. Bambauer R., Schwarze U., Schiel R. Cyclosporin A and therapeutic plasma exchange in the treatment of severe systemic lupus erythematosus. Artif Organs 2000, 24(11):852-856.
48. Neuwelt C.M. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial 2003, 7(2):173-182.
49. Schroeder J.O., Euler H.H. Treatment combining plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Adv Exp Med Biol 1989, 260:203-213.
50. Canas C., Tobon G.J., Granados M., et al. Diffuse alveolar hemorrhage in Colombian patients with systemic lupus erythematosus. Clin Rheumatol 2007, 26(11):1947-1949.
51. Wei N., Klippel J.H., Huston D.P., et al. Randomised trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1983, 1(8314-5):17-22.
52. Hanly J.G., Hong C., Zayed E., et al. Immunomodulating effects of synchronised plasmapheresis and intravenous bolus cyclophosphamide in systemic lupus erythematosus. Lupus 1995, 4(6):457-463.
53. Ferenci P. Pathophysiology and clinical features of Wilson disease. Metab Brain Dis 2004, 19(3-4):229-239.
54. Asfaha S., Almansori M., Qarni U., et al. Plasmapheresis for hemolytic crisis and impending acute liver failure in Wilson disease. J Clin Apher 2007, 22(5):295-298.
55. Hursitoglu M., Kara O., Cikrikcioglu M.A., et al. Clinical improvement of a patient with severe Wilson's disease after a single session of therapeutic plasma exchange. J Clin Apher 2009, 24(1):25-27.
56. Jhang J.S., Schilsky M.L., Lefkowitch J.H., et al. Therapeutic plasmapheresis as a bridge to liver transplantation in fulminant Wilson disease. J Clin Apher 2007, 22(1):10-14.
57. Kiss J.E., Berman D., Van Thiel D. Effective removal of copper by plasma exchange in fulminant Wilson's disease. Transfusion 1998, 38(4):327-331.
58. Nagata Y., Uto H., Hasuike S., et al. Bridging use of plasma exchange and continuous hemodiafiltration before living donor liver transplantation in fulminant Wilson's disease. Intern Med 2003, 42(10):967-970.
59. Lee W.M. Acute liver failure. Semin Respir Crit Care Med 2012, 33(1):36-45.
60. Clemmesen J.O., Kondrup J., Nielsen L.B., et al. Effects of high-volume plasmapheresis on ammonia, urea, and amino acids in patients with acute liver failure. Am J Gastroenterol 2001, 96(4):1217-1223.
61. Ahboucha S., Gamrani H., Baker G. GABAergic neurosteroids: The "endogenous benzodiazepines" of acute liver failure. Neurochem Int 2011, [Epub ahead of print].
62. Akdogan M., Camci C., Gurakar A., et al. The effect of total plasma exchange on fulminant hepatic failure. J Clin Apher 2006, 21(2):96-99.
63. De Silvestro G., Marson P., Brandolese R., et al. A single institution's experience (1982-1999) with plasma-exchange therapy in patients with fulminant hepatic failure. Int J Artif Organs 2000, 23(7):454-461.
64. Singer A.L., Olthoff K.M., Kim H., et al. Role of plasmapheresis in the management of acute hepatic failure in children. Ann Surg 2001, 234(3):418-424.
65. Rydberg L. ABO-incompatibility in solid organ transplantation. Transfus Med 2001, 11(4):325-342.
66. Roche S.L., Burch M., O'Sullivan J., et al. Multicenter experience of ABO-incompatible pediatric cardiac transplantation. Am J Transplant 2008, 8(1):208-215.
67. West L.J., Pollock-Barziv S.M., Dipchand A.I., et al. ABO-incompatible heart transplantation in infants. N Engl J Med 2001, 344(11):793-800.
68. Carithers R.L. Liver transplantation. American Association for the Study of Liver Diseases. Liver Transpl 2000, 6(1):122-135.
69. Winters J.L., Gloor J.M., Pineda A.A., et al. Plasma exchange conditioning for ABO-incompatible renal transplantation. J Clin Apher 2004, 19(2):79-85.
70. Tobian A.A., Shirey R.S., Montgomery R.A., et al. Therapeutic plasma exchange reduces ABO titers to permit ABO-incompatible renal transplantation. Transfusion 2009, 49(6):1248-1254.
71. Khurana D.S., Melvin J.J., Kothare S.V., et al. Acute disseminated encephalomyelitis in children: discordant neurologic and neuroimaging abnormalities and response to plasmapheresis. Pediatrics 2005, 116(2):431-436.
72. Lin C.H., Jeng J.S., Yip P.K. Plasmapheresis in acute disseminated encephalomyelitis. J Clin Apher 2004, 19(3):154-159.
73. RamachandranNair R., Rafeequ M., Girija A.S. Plasmapheresis in childhood acute disseminated encephalomyelitis. Indian Pediatr 2005, 42(5):479-482.
74. Garg R.K. Acute disseminated encephalomyelitis. Postgrad Med J 2003, 79(927):11-17.
75. Kaynar L., Altuntas F., Aydogdu I., et al. Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study. Transfus Apher Sci 2008, 38(2):109-115.
76. Keegan M., Pineda A.A., McClelland R.L., et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002, 58(1):143-146.
77. Menge T., Hemmer B., Nessler S., et al. Acute disseminated encephalomyelitis: an update. Arch Neurol 2005, 62(11):1673-1680.
78. Johnson J.P., Moore J., Austin H.A., et al. Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) 1985, 64(4):219-227.
79. Levy J.B., Turner A.N., Rees A.J., et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001, 134(11):1033-1042.
80. Simpson I.J., Doak P.B., Williams L.C., et al. Plasma exchange in Goodpasture's syndrome. Am J Nephrol 1982, 2(6):301-311.
81. Lazor R., Bigay-Game L., Cottin V., et al. Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases. Medicine (Baltimore) 2007, 86(3):181-193.
82. Zauner I., Bach D., Braun N., et al. Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis. Am J Kidney Dis 2002, 39(1):28-35.
83. Little M.A., Pusey C.D. Rapidly progressive glomerulonephritis: current and evolving treatment strategies. J Nephrol 2004, 17(Suppl 8):S10-S19.
84. Frasca G.M., Soverini M.L., Falaschini A., et al. Plasma exchange treatment improves prognosis of antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis: a case-control study in 26 patients from a single center. Ther Apher Dial 2003, 7(6):540-546.
85. Klemmer P.J., Chalermskulrat W., Reif M.S., et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003, 42(6):1149-1153.
86. de Lind van Wijngaarden R.A., Hauer H.A., Wolterbeek R., et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 2006, 17(8):2264-2274.
87. Jayne D.R., Gaskin G., Rasmussen N., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007, 18(7):2180-2188.
88. Henter J.I., Horne A., Arico M., et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007, 48(2):124-131.
89. Jordan M.B., Allen C.E., Weitzman S., et al. How I treat hemophagocytic lymphohistiocytosis. Blood 2011, 118(15):4041-4052.
90. Castillo L., Carcillo J. Secondary hemophagocytic lymphohistiocytosis and severe sepsis/systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med 2009, 10(3):387-392.
91. Coman T., Dalloz M.A., Coolen N., et al. Plasmapheresis for the treatment of acute pancreatitis induced by hemophagocytic syndrome related to hypertriglyceridemia. J Clin Apher 2003, 18(3):129-131.
92. Imashuku S., Hibi S., Ohara T., et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. Blood 1999, 93(6):1869-1874.
93. Ladisch S., Ho W., Matheson D., et al. Immunologic and clinical effects of repeated blood exchange in familial erythrophagocytic lymphohistiocytosis. Blood 1982, 60(4):814-821.
94. Nakakura H., Ashida A., Matsumura H., et al. A case report of successful treatment with plasma exchange for hemophagocytic syndrome associated with severe systemic juvenile idiopathic arthritis in an infant girl. Ther Apher Dial 2009, 13(1):71-76.
95. Raschke R.A., Garcia-Orr R. Hemophagocytic lymphohistiocytosis: a potentially underrecognized association with systemic inflammatory response syndrome, severe sepsis, and septic shock in adults. Chest 2011, 140(4):933-938.
96. Sanada S., Ookawara S., Shindo T., et al. A case report of the effect of plasma exchange on reactive hemophagocytic syndrome associated with toxic shock syndrome. Ther Apher Dial 2004, 8(6):503-506.
97. Satomi A., Nagai S., Nagai T., et al. Effect of plasma exchange on refractory hemophagocytic syndrome complicated with myelodysplastic syndrome. Ther Apher 1999, 3(4):317-319.
98. Song K.S., Sung H.J. Effect of plasma exchange on the circulating IL-6 levels in a patient with fatal hemophagocytic syndrome associated with bile ductopenia. Ther Apher Dial 2006, 10(1):87-89.
99. Zhang X.Y., Ye X.W., Feng D.X., et al. Hemophagocytic lymphohistiocytosis induced by severe pandemic influenza A (H1N1) 2009 virus infection: a case report. Case Report Med 2011, 2011:951910.
100. Demirkol D., Yildizdas D., Bayrakci B., et al. Hyperferritinemia in the critically ill child with secondary HLH/sepsis/MODS/MAS: what is the treatment?. Crit Care 2012, 16(2):R52.